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Abstract. Exosomes serve important functions in cell-to-cell 
communication and biological functions by serving as a 
delivery cargo shuttle for various molecules. The application of 
an improved delivery method for microRNAs (miRNAs/miRs) 
may enhance their potential as a therapeutic tool in cardiac 
diseases. Thus, the present study investigated whether 
human peripheral blood-derived exosomes may be used as a 
delivery cargo system for miRNAs, and whether the delivery 
of miR-21 using a human peripheral blood derived-exosome 
may influence the degree of remodeling following myocardial 
infarction (MI). In H9c2 and HL-1 cells, miR-21 expression 
was successfully regulated by treatment with human peripheral 
blood derived-exosomes loaded with an miR-21 mimic or 
inhibitor compared with untreated cells. In addition, the mRNA 
and protein expression levels of SMAd family member 7 
(Smad7), phosphatase and tensin homolog (PTEN) and matrix 
metalloproteinase 2 (MMP2), which are involved in cardiac 
fibrosis, were associated with the uptake of miR‑21 mimic‑ or 
inhibitor-loaded exosomes. Similarly, the in vivo mRNA and 
protein expression of Smad7, PTEN and MMP2 were altered 
following treatment with miR-21 mimic- or inhibitor-loaded 
exosomes. Furthermore, miR-21 mimic-loaded exosomes 
enhanced fibrosis, whereas miR‑21 inhibitor‑loaded exosomes 
reduced fibrosis in a mouse MI model. These results suggested 
that miRNA-loaded human peripheral blood derived-exosomes 
may be used as a therapeutic tool for cardiac diseases.
Introduction
Myocardial infarction (MI), also known as a heart attack, 
is one of the leading causes of mortality globally (1). death 
of cardiomyocytes, angiogenesis, fibrosis, hypertrophy and 
contractile dysfunction during MI result in impaired cardiac 
function (2‑5). In particular, cardiac fibrosis following MI 
serves a key function in regulating cardiac function (6). In 
addition, it has been identified as a key factor in the incidence 
of heart failure, as excessive fibrosis results in ventricular dila-
tion, infarct expansion and hypertension (7). For this reason, 
inhibition of cardiac fibrosis progression in infarcted hearts 
may preserve cardiac function and prevent heart failure. 
However, at present, there is no efficient therapy available (8).
Exosomes, membrane-bound vesicles of 30-100 nm, are 
secreted by various cell types and are present in the majority 
of body fluids (9,10). An exosome is a ‘nanosphere’ with a 
bilayered membrane, containing various types of lipids and 
proteins. For example, the majority of exosomes contain 
membrane transport and fusion proteins, heat‑shock proteins, 
multivesicular body biogenesis proteins [including programmed 
cell death 6 interacting protein (Alix)], tetraspanin [including 
cluster of differentiation (CD)9, CD63 and CD81] and 
endosomal/lysosomal proteins [including lysosomal associated 
membrane protein 2 (LAMP2)]. In addition, exosomes are 
comprised of different types of lipids, including cholesterol, 
sphingolipids, phosphoglycerides, ceramides and saturated 
fatty acid chains. These exosome compositions function as 
cargo for cell-to-cell communication (11,12). Lately, exosomes 
have emerged as a promising drug delivery system with lower 
toxicity compared with conventional delivery systems and high 
therapeutic efficacy (13). However, two of the major challenges 
in developing exosome-based drug delivery methods are the 
scale up procedure and utilization without side effects (14). 
As human peripheral blood is widely used for transfusion and 
is easily obtained, the use of human peripheral blood-derived 
exosomes as a microRNA (miRNA/miR) delivery system, has 
substantial potential as a therapeutic tool.
Previous studies have demonstrated that certain miRNAs 
function as essential modulators in a number of physiological 
and pathological MI processes, including fibrosis (15-17). 
Among various miRNAs, miR-21 serves a crucial role in the 
development of cardiac fibrosis in response to MI through 
numerous target genes, including SMAd family member 7 
(Smad7), sprout RTK signaling antagonist 1 and phosphatase 
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and tensin homolog (PTEN) (18-20). Thus, the function of 
miR‑21 in regulating gene expression during fibrosis makes 
miR-21 an ideal candidate for therapeutic applications.
The present study aimed to investigate whether exosomes 
isolated from human peripheral blood may function as efficient 
vehicles for miRNA delivery. To achieve this aim, miR-21, 
a well‑known therapeutic target for cardiac diseases, was 
transfected into human peripheral blood-derived exosomes 
and whether the exosomes may deliver the miRNA in in vitro 
and in vivo models was evaluated. Furthermore, whether 
exosomes loaded with an miR-21 inhibitor may modulate the 
fibrotic remodeling in an MI mouse model was investigated. 
Therefore, the present study may provide a potential, effective 
approach for the treatment of cardiac disease.
Patients and methods
Exosome isolation and characterization. Human peripheral 
blood was obtained from three patients without serious or 
progressive cardiac disease at Yonsei University Health 
System (Seoul, Korea) from August 2015 to July 2016; the 
clinical profile of the patients is presented in Table I. Written 
informed consent was obtained from all patients and the study 
protocol was ethically approved by the local ethics committee 
(Institutional Review Board of Severance Hospital (Seoul, 
Korea) of the Yonsei University Health System; approval no. 
YUMc 4-2011-0872). Exosomes were isolated from human 
peripheral blood using the Exoquick exosome precipitation kit 
(System Biosciences, Palo Alto, cA, USA) according to the 
manufacturer's protocol. Briefly, human peripheral blood was 
centrifuged at 3,000 x g for 15 min at 4˚C to remove cells 
and cellular debris. Exoquick Exosome Precipitation Solution 
(63 µl) was added to 250 µl supernatant, transferred to a sterile 
tube, and incubated for 12 h at 4˚C. Following incubation, the 
mixtures were centrifuged at 1,500 x g for 30 min at 4˚C and 
the supernatant was removed by aspiration. Exosome pellets 
were resuspended in 200 µl Dulbecco's phosphate‑buffered 
saline (PBS), aliquoted to avoid freeze and thaw cycles, and 
stored at ‑80˚C.
For transmission electron microscopy (TEM), exosomes 
were prepared in PBS. The samples were adsorbed to a 
Formvar-carbon-coated electron microscope grid (Leica 
Microsystems, Inc., Buffalo Grove, IL, USA) for ~1 min and 
the grid surface was then touched for 15 sec with 2% uranyl 
acetate. Exosome size and morphology were observed using 
a JEM‑1011 electron microscope (JEOL Ltd., Tokyo, Japan).
Nanopaticle tracking analysis (NTA) was performed to 
measure the size distribution and concentration of exosomes 
using a NanoSight LM10 instrument (Malvern Instruments, 
Ltd., Malvern, UK). The samples were captured for 60 sec at 
room temperature with a flow rate of 50 ml/min, and the data 
was obtained using NTA v.3.2 software (Malvern Panalytical, 
Ltd., Malvern, UK), which allows videos of particles moving 
under Brownian motion to be captured and automatically 
analyzed to generate high-resolution size distribution and 
concentration data.
Isolated exosomes were labeled using the PKH26 
Red Fluorescent Cell Linker kit (Sigma‑Aldrich; Merck 
KGaA, darmstadt, Germany) according to the manufac-
turer's protocol. Next, unlabeled or PKH26 red fluorescent 
dye-labeled exosomes were added to H9c2 and HL-1 cell 
lines obtained from the American Type culture collection 
(ATCC, Manassas, VA, USA) and incubated for 24 h at 37˚C in 
5% cO2. The cardiac cells were washed twice with PBS, fixed 
with 4% paraformaldehyde for 30 min at room temperature 
and stained with dAPI for 5 min at room temperature. The 
uptake of exosomes by cardiac cell lines was observed using a 
confocal microscope (carl Zeiss, Jena, Germany).
miRNA transfection into exosomes. The negative control 
miRNA (cat. no. SMc-2003), miR-21 mimic (5'-UAG cUU 
AUc AGA cUG AUG UUG A-3'; cat. no. SMM-002) and 
miR-21 inhibitor (5'-AUc GAA UAG UcU GAc UAc AAc U-3'; 
cat. no. SMI-002) were obtained from Bioneer corporation 
(daejoen, Korea). The miRNAs were transfected into human 
peripheral blood-derived exosomes using the Exo-Fect™ 
Exosome Transfection kit (System Biosciences) according 
to the manufacturer's protocol. Next, the exosomes were 
washed twice using Amicon ultra centrifugation tubes (EMd 
Millipore, Billerica, MA, USA) with cold PBS. The transfected 
exosomes were directly used for further experiments.
Cell culture and hypoxia. H9c2 cardiac muscle cells, purchased 
from the American Type culture collection (ATcc), were 
grown in dulbecco's modified Eagle's medium (WelGENE, 
Inc., daegu, Korea) supplemented with 10% fetal bovine 
serum (FBS; Young In Frontier co., Ltd., Seoul, Korea) and 
1% penicillin‑streptomycin (Gibco; Thermo Fisher Scientific, 
Inc., Waltham, MA, USA). HL-1 cardiac muscle cells were 
obtained from ATcc. cells were maintained in complete 
claycomb Medium (SAFc Biosciences, Lenexa, KS, USA) 
supplemented with 10% FBS, 1% penicillin-streptomycin, 
100 µM norepinephrine (Sigma‑Aldrich; Merck KGaA) and 
4 mM L‑glutamine (Gibco; Thermo Fisher Scientific, Inc.) in 
plates coated with 12.5 µg/ml fibronectin and 0.02% gelatin (both 
Sigma‑Aldrich; Merck KGaA). To induce hypoxia, cells were 
placed in Forma™ Series II 3131 Water‑Jacketed CO2 incubators 
(Thermo Fisher Scientific, Inc.) with 94% N2, 5% cO2 and 1% O2 
at 37˚C for 24 h. The corresponding normoxic control cells were 
maintained at 37˚C in a humidified incubator with 5% CO2 and 
21% O2. Following treatment with transfected exosomes into 
H9C2 and HL‑1 cells for 24 h at 37˚C, the cells were exposed to 
hypoxia for a further 24 h.
Reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR). Total RNA from cultured cells and mouse heart 
tissues was extracted using the miRNeasy Mini kit (Qiagen 
GmbH, Hilden, Germany) according to the manufacturer's 
protocols. complementary dNA was synthesized using the 
miRNA 1st‑Strand cDNA Synthesis kit (Agilent Technologies, 
Inc., Santa clara, cA, USA) and the High capacity cdNA 
Reverse Transcription kit (Applied Biosystems; Thermo Fisher 
Scientific, Inc.) according to the manufacturer's protocol. 
RT-qPcR was performed on an AriaMx Realtime PcR System 
using the Brilliant III Ultra-Fast SYBR®‑Green QPCR Master 
Mix (both Agilent Technologies, Inc.). The reaction conditions 
were as follows: 95˚C for 3 min followed by 40 cycles at 95˚C for 
3 sec and 55˚C for 20 sec. The PCR primers were synthesized 
by cosmo Genetech co., Ltd. (daejeon, Korea) and are listed in 
Table II. The relative expression levels of the miRNAs and the 
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miR-21 target genes were calculated using the 2-ΔΔcq method (21) 
and normalized against U6 and GAPDH, respectively.
Western blot analysis. Total protein from cultured 
cells and mouse hear t tissues was extracted with 
radioimmunoprecipitation assay Lysis and Extraction Buffer 
containing Protease and Phosphatase Inhibitor Cocktail (both 
Thermo Fisher Scientific, Inc.). The protein concentration 
of cell and tissue lysates was determined using a Pierce™ 
660 nm Protein Assay reagent (Thermo Fisher Scientific, Inc.). 
Equal amounts of cell (20 µg) and tissue lysates (60 µg) were 
separated on a 10% Gradi-Gel™ II gradient gel (Elpis Biotech, 
Inc., daejeon, Korea) and transferred to polyvinylidene 
difluoride membranes (EMD Millipore, Billerica, MA, USA). 
The membranes were subsequently blocked for 1 h at room 
temperature in tris-buffered saline (TBS)-0.1% Tween 20 
(TBS-T) containing 5% bovine serum albumin and incubated 
overnight at 4˚C with primary antibodies against the following 
proteins: Alix (cat. no. sc-53540; 1:1,000), LAMP2 (cat. 
no. sc-18822; 1:1,000; both Santa cruz Biotechnology Inc., 
dallas, TX, USA), cd9 (cat. no. EXOAB-cd9A-1; 1:1,000), 
CD63 (cat. no. EXOAB‑CD63A‑1; 1:1,000; both System 
Biosciences), CD81 (cat. no. sc‑166029; 1:1,000), Smad7 (cat. 
no. sc‑365846; 1:1,000), PTEN (cat. no. sc‑7974; 1:1,000; all 
Santa cruz Biotechnology Inc.), matrix metalloproteinase 2 
(MMP2; cat. no. ab37150; 1:1,000; Abcam, cambridge, 
UK) and GAPDH (cat. no. sc‑166574; 1:1,000; Santa Cruz 
Biotechnology Inc.). GAPdH was used as the loading control. 
Following three washes with TBS-T, the membranes were 
incubated with horseradish peroxidase-conjugated goat 
anti-mouse IgG-HRP (cat. no. sc-2005; 1:5,000) and goat 
anti-rabbit IgG-HRP (cat. no. sc-2004; 1:5,000; both Santa 
cruz Biotechnology Inc.) for 1 h at room temperature. Blotted 
proteins were visualized using an enhanced chemiluminescence 
kit (Santa Cruz Biotechnology Inc.).
Animal experiments. A total of 20 adult male c57BL/6 mice 
(8 weeks old; 20‑25 g) were purchased from the Orient Bio 
Inc. (Seongnam, Korea). All mice were maintained under 
standard conditions (temperature, 20±0.5˚C; humidity, 
60±5%; light/dark cycle, 12 h), and allowed free access to 
food and water. The mice were anesthetized by intraperitoneal 
injections of ketamine (100 mg/kg) and xylazine (Rompun®, 
10 mg/kg) and maintained with a positive pressure ventilation 
using a ventilator (Harvard Apparatus co., Millis, MA, 
USA). MI was then induced by ligation of the left anterior 
descending coronary artery with a 6‑0 silk suture (Ethicon, 
Inc., cincinnati, OH, USA). Prior to injecting into the MI 
mice, negative control miRNA, miR-21 mimic or miR-21 
inhibitor at a final concentration of 5 µmol/ml were loaded 
into a 200 µl exosome sample containing 1 µg/µl exosomal 
proteins using the Exoquick exosome precipitation kit (System 
Biosciences) according to the manufacturer's protocol. Next, 
exosomes containing negative control miRNA, miR-21 mimic 
Table I. Clinical profile of patients from whom exosomes were isolated.
case Sex/age diagnosis Medication
1 Female/66 Atrial flutter Amiodarone
2 Female/77 Atrial flutter, hypertension Verapamil
3 Male/67 Paroxysmal supraventricular tachycardia, hypertension Perindopril
Table II. Primers used for reverse transcription-quantitative polymerase chain reaction.






mmu‑Collagen Ⅰ CATGTTCAGCTTTGTGGACCT GCAGCTGACTTCAGGGATGT








miR, microRNA; Smad7, SMAd family member 7; PTEN, phosphatase and tensin homolog; MMP2, matrix metalloproteinase 2.
KANG et al:  HUMAN PERIPHERAL BLOOd-dERIVEd EXOSOMES FOR microRNA dELIVERY2322
or inhibitor were administered by three intra-myocardial 
injections (total 100 µl) into the infarct border zone, as 
previously described (22,23). The mice were divided into the 
following five groups (four mice/group): i) non-MI, ii) MI, 
iii) MI + negative control miRNA-loaded exosome injection, 
iv) MI + miR-21 mimic-loaded exosome injection and v) MI 
+ miR-21 inhibitor-loaded exosome injection. cardiac tissues 
were obtained from the left ventricular (LV) infarcted zone, 
infarct border zone and remote zone in the MI mice and from the 
LV apex in the non-MI mice. All procedures were performed 
in accordance with the ethical approval of the Institutional 
Animal care and Use committee of Yonsei University college 
of Medicine (approval reference no. 2011‑0136) and the Guide 
for the care and Use of Laboratory Animals published by the 
National Institutes of Health (24).
Echocardiography was performed with a Vevo 2100 
system (VisualSonics, Inc., Toronto, ON, canada). LV ejection 
fraction (LVEF) and fractional shortening (FS) were calculated 
according to the following formulas: LVEF (%) = [left 
ventricular end-diastolic volume (LVEdV)-left ventricular 
end-systolic volume /LVEdV) x100; left ventricular fractional 
shortening (LVFS) (%) = left ventricular internal-diastolic 
diameter (LVIdd)-left ventr icular internal-systolic 
diameter)/LVIdd x100.
The mice were sacrificed one week following the treat-
ment and the cardiac tissue were quickly collected and fixed 
in 4% formaldehyde for seven days at room temperature. 
Tissues were embedded in paraffin and sliced into 4 µm thick 
sections. Next, the sections were mounted on normal glass 
slides and stained with hematoxylin and eosin (H&E) for 
2 min at room temperature and Masson's Trichrome (MT) 
for 10 min at room temperature. Four hearts were analyzed 
in each group and five distinct fields were examined in each 
slide, resulting in the evaluation of 20 fields in total from each 
group. Each slide was examined using an optical microscope 
and quantified with ImageJ 1.50i software (National Institutes 
of Health, Bethesda, Md, USA).
Statistical analysis. The data are presented as the mean ± stan-
dard deviation (n=4). The comparisons between the 
experimental groups were conducted using either an unpaired 
two-tailed Student's t-test, or a one-way analysis of vari-
ance with a Student-Newman-Keuls post hoc test. Statistical 
analyses were performed using SPSS version 23.0 (SPSS, 
Inc., chicago, IL, USA) and GraphPad Prism 5 (GraphPad 
Software, Inc., La Jolla, cA, USA). P<0.05 was considered to 
indicate a statistically significant difference.
Results
Characterization of human peripheral blood‑derived 
exosomes. Exosomes isolated from human peripheral blood 
were examined by TEM, NTA and western blot analysis. 
TEM analysis revealed that the isolated exosomes had a 
typical round morphology (Fig. 1A) and NTA revealed that 
the isolated exosomes had a mean particle size distribution 
of 104 nm (Fig. 1B). consistent with these results, western 
blot analysis demonstrated the presence of known exosome 
markers, including Alix, LAMP2, CD9, CD63 and CD81, 
in the exosomes. The exosomes revealed high expression of 
markers, but GAPDH was absent (Fig. 1C). The detection of 
shape, size and protein markers of typical exosomes indicated 
that the exosomes were successfully isolated from human 
peripheral blood. To further investigate whether human 
peripheral blood‑derived exosomes were taken up by cardiac 
cell lines, the exosomes with were labelled with PKH26, a 
red florescent dye. After 24 h treatment of H9C2 and HL‑1 
cells with labeled exosomes, a positive PKH26 signal was 
validated using confocal microscopy (Fig. 1d). These 
observations suggest that human peripheral blood-derived 
exosomes were effectively absorbed in the two cardiac cell 
lines.
Exosome‑mediated delivery of miRNA in vitro. In order to 
determine the miRNA delivery potential of human peripheral 
blood derived-exosomes in vitro, exosomes were loaded 
with either miR-21 mimic or inhibitor using the Exo-Fect™ 
Exosome Transfection reagent (Fig. 2A). Following treatments 
with miR-21 mimic- or inhibitor-loaded exosomes in H9c2 
and HL-1 cells, RT-qPcR was performed to measure the levels 
of miR-21. Under normoxic conditions, miR-21 expression 
levels in H9C2 and HL‑1 cells were significantly upregulated 
following treatment with miR-21 mimic-loaded exosomes 
compared with normoxic controls (P<0.01; Fig. 2B and F). 
Next, it was detected that miR-21 expression was upregulated 
in hypoxic cardiac cells compared with normoxic controls and 
that miR-21 expression was regulated by the presence of its 
mimic and inhibitor when compared to the hypoxic controls. 
Under the conditions of hypoxic H9c2 cells, miR-21 mimic 
and inhibitor significantly upregulated and downregulated 
miR-21 expression compared with hypoxic controls, 
respectively (P<0.05; Fig. 2c). Similarly, in hypoxic HL-1 
cells, miR‑21 mimic‑loaded exosomes significantly increased 
miR-21 expression compared with the normoxic and hypoxic 
controls (P<0.01), whereas miR-21 inhibitor-loaded exosomes 
significantly reduced miR‑21 expression (P<0.005; Fig. 2G). 
collectively, these observations suggest that human peripheral 
blood-derived exosomes effectively delivered miR-21 mimic 
or inhibitor to the two cardiac cell lines under all tested 
conditions.
It is well known that miRNAs exert their functions via 
the suppression of their target gene expression by binding to 
the 3'‑untranslated region of target mRNAs (25,26); thus, the 
present study next examined the mRNA and protein expres-
sion levels of Smad7, a direct target of miR-21, previously 
implicated in fibrosis regulation (19,27). It was observed that 
treatment with miR-21 mimic-loaded exosomes in H9c2 
cells significantly downregulated the mRNA and protein 
expression levels of Smad7 compared with hypoxic controls 
and that the expression of Smad7 was significantly upregu-
lated in cells treated with miR-21 inhibitor-loaded exosomes 
(P<0.05; Fig. 2d and E). Similarly, in HL-1 cells, hypoxia 
induced the significantly reduced expression levels of Smad7 
mRNA and protein compared with normoxic controls, which 
were downregulated by miR-21 mimic- and upregulated by 
miR-21 inhibitor-loaded exosomes (P<0.05; Fig. 2H and I). 
Altogether, these results demonstrate that miR-21 mimic- or 
inhibitor‑loaded exosomes were effectively delivered into 
cardiac cells and exhibited therapeutic potential by regulating 
target genes associated with physiopathological mechanisms.
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Regulation of functional target using miRNA‑loaded exosomes. 
Furthermore, the present study assessed the expression of 
PTEN, a well‑known direct target of miR‑21 (28), in order to 
validate the efficiency of exosomes as a delivery system. PTEN 
is expressed in various cell types, including cardiomyocytes, 
fibroblasts, endothelial cells and vascular smooth muscle 
cells, where it modulates cell survival/apoptosis, hypertrophy, 
contractility, fibrosis and metabolism (28,29). Hence, 
PTEN is a crucial molecule involved in the development of 
numerous cardiovascular diseases (30). It was observed that 
miR-21 mimic-loaded exosomes significantly suppressed 
PTEN expression compared with hypoxic controls, whereas 
miR-21 inhibitor-loaded exosomes significantly promoted 
PTEN expression compared with H9c2 and HL-1 cells 
treated with miR-21 mimic-loaded exosomes (P<0.05; 
Fig. 3A-d). In addition, previous reports have demonstrated 
that miR-21-regulated expression of MMP-2 is modulated via 
a PTEN pathway and results in cardiac fibrosis (18,31). In the 
two cell lines, miR‑21 mimic‑loaded exosomes significantly 
increased MMP-2 expression compared with hypoxic controls, 
whereas miR-21 inhibitor-loaded exosomes significantly 
reduced MMP-2 expression compared to cells treated with 
miR-21 mimic-loaded exosomes (P<0.05; Fig. 3A-d).
Exosome‑mediated delivery of miRNA in vivo. c57BL/6 mice 
were subjected to MI to evaluate miR-21 expression levels in 
the infarcted, border and remote zones. MiR-21 expression 
levels were significantly upregulated in the MI mouse model, 
compared with non-MI mice, particularly in the infarcted zone 
of the heart (P<0.05; Fig. 4A). Next, the expression levels of 
Smad7, PTEN and MMP2 were assessed using RT-qPcR and 
western blot analysis to determine whether miR-21 mimic- or 
inhibitor‑loaded exosomes were delivered efficiently in vivo. 
Similar to the results of in vitro experiment, it was observed 
that the mRNA and protein expression levels of Smad7, PTEN 
and MMP2 were significantly altered following treatment with 
miR-21 mimic-loaded exosomes when compared with mice 
treated with inhibitor-loaded exosomes(P<0.05; Fig. 4B and c).
Therapeutic potential of miRNA‑loaded exosomes against 
cardiac fibrosis. Finally, the present study investigated the 
potential of human peripheral blood-derived exosomes to 
deliver miRNA for the treatment of cardiac fibrosis following 
MI. The echocardiography analysis revealed worse cardiac 
function in mice treated with miR-21 mimic-loaded exosomes 
compared with mice treated with miR-21 inhibitor-loaded 
exosomes, as the former group of mice exhibited significantly 
decreased LVEF and LVFS compared with the latter group 
of mice (P<0.05; Fig. 5A). As observed following the H&E 
and MT staining, myocardial disorders and fibrosis were 
significantly enhanced in MI mice compared with non‑MI 
mice (P<0.05). Histological examination of the hearts of 
mice treated with miR-21 mimic-loaded exosomes revealed 
the dilatation of the left ventricular chambers with thinning 
of the walls. However, the histological changes were reduced 
following treatment with miR-21 inhibitor-loaded exosomes. 
In addition, cardiac fibrosis at the infarcted and border zones 
increased in mice treated with miR-21 mimic-loaded exosomes 
compared with MI mice, and this effect was reversed by treat-
ment with miR-21 inhibitor-loaded exosomes (Fig. 5B and c).
Furthermore, the expression levels of myocardial fibrosis 
markers, collagen I and III, were significantly upregulated 
in MI mice compared with non-MI mice. Mice treated with 
miR-21 mimic- or inhibitor-loaded exosomes significantly 
upregulated and downregulated collagen I and III expres-
sion levels, respectively (P<0.05; Fig. 5d). collectively, 
Figure 1. Characterization of exosomes isolated from human peripheral blood and uptake of exosomes by cardiac cells. (A) Morphology of human peripheral 
blood-derived exosomes imaged using transmission electron microscopy (scale bar, 200 nm). (B) Human peripheral blood particle size/concentration were 
analyzed by nanoparticle tracking analysis. (C) Protein expression were determined using western blot analysis using the indicated exosome marker antibodies. 
(D) H9C2 and HL‑1 cells were treated with unlabeled or PKH26 (red)‑labeled exosomes for 24 h and analyzed by confocal microscopy (scale bar, 20 µm; 
magnification, x800). Cell nuclei were stained with DAPI (blue). Alix, programmed cell death 6 interacting protein; LAMP2, lysosomal associated membrane 
protein 2; cd, cluster of differentiation.
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these results revealed that human peripheral blood-derived 
exosomes successfully delivered miR-21 mimics or inhibitors 
and modulated cardiac fibrosis in vivo. Thus, the regulation 
of mRNAs using miRNA-loaded exosomes derived from the 
human peripheral blood may represent an effective therapeutic 
approach against cardiac fibrosis following MI.
Discussion
MI is a public health problem and a leading cause of mortality 
globally (32). The development of impaired cardiac func-
tion and cardiac fibrosis due to MI serves a key function in 
regulating cardiac dysfunction (6,33). Currently, no efficient 
therapies are available that may inhibit the progression of 
cardiac fibrosis in infarcted hearts (8). Thus, in the present 
study, it was examined whether miRNA delivery using human 
peripheral blood-derived exosomes may function as an effec-
tive therapeutic approach against MI by modulating cardiac 
fibrosis.
To date, a number of studies have suggested that extra-
cellular vesicles (EVs) from in vitro cultured-cells or serum 
possess cardioprotective effects due to miRNAs, already 
present in the EVs (34,35); however, these studies have focused 
on the function of EVs as protective vesicles as opposed to 
drug carriers. Notably, the present study, to the best of our 
knowledge, provides the first compelling evidence that human 
peripheral blood-derived exosomes may be successfully used 
as a delivery vehicle for miRNA.
miRNAs comprise a broad class of small non-coding 
RNAs that control the expression of complementary target 
mRNAs (36). Dysregulation of miRNAs by a number of 
mechanisms has been observed in various diseases including 
Figure 2. delivery of miR-21 mimic- or inhibitor-loaded exosomes into cardiac cells. (A) Experimental procedure for miRNA delivery using human periph-
eral blood-derived exosomes. Human peripheral blood-derived exosomes were loaded with miR-21 mimic or inhibitor and then used for transfection into 
H9c2 and HL-1 cells. Subsequent to 24 h treatment, the two cardiac cell lines were exposed to hypoxia for 24 h. MiR-21 expression in (B and c) H9c2 and 
(F and G) HL‑1 cells was measured and normalized against U6. Smad7 mRNA expression in (D) H9C2 and (H) HL‑1 cells was determined using reverse 
transcription-quantitative polymerase chain reation. GAPdH was used as the internal control. Smad7 protein expression was detected by western blot 
analysis in (E) H9c2 and (I) HL-1 cells. *P<0.05, **P<0.01 and ***P<0.005 with comparisons shown by lines. miR/miRNA, microRNA; Exo/Nc, negative 
control miRNA-loaded exosome injection; Exo/21-M, miR-21 mimic-loaded exosome injection; Exo/21-I, miR-21 inhibitor-loaded exosome injection; 
Smad7, SMAd family member 7.
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Figure 3. Effect of miR-21 mimic- or inhibitor-loaded exosomes on the modulation of target gene expression. PTEN and MMP2 expression levels following 
treatment with miR-21 mimic- or inhibitor-loaded exosomes were evaluated in (A and B) H9c2 and (c and d) HL-1 cells. (A and c) mRNA levels were measured 
using reverse transcription-quantitative polymerase chain reaction. (B and d) Protein levels were measured by western blot analysis. *P<0.05, **P<0.01 and 
***P<0.005 with comparisons shown by lines. miR, microRNA; PTEN, phosphatase and tensin homolog; MMP2, matrix metalloproteinase 2; Exo/Nc, negative 
control miRNA-loaded exosome injection; Exo/21-M, miR-21 mimic-loaded exosome injection; Exo/21-I, miR-21 inhibitor-loaded exosome injection.
Figure 4. delivery of miR-21 mimic- or inhibitor-loaded exosomes to MI mouse model. (A) RT-qPcR was used to determine miR-21 levels in different 
regions (infarcted, border zone and remote zone) of non‑MI and MI mice. Relative miR‑21 levels were normalized against U6. (B) Following an injection of 
miR-21 mimic- or inhibitor-loaded exosomes into the MI mouse model, Smad7, PTEN and MMP2 mRNA expression levels were determined usong RT-qPcR. 
(c) Smad7, PTEN and MMP2 protein levels were detected using western blot analysis. *P<0.05, **P<0.01 and ***P<0.005 with comparisons shown by lines. 
MI, myocardial infarction; miR, microRNA; RT-qPcR, reverse transcription-quantitative polymerase chain reaction; Smad7, SMAd family member 7; 
PTEN, phosphatase and tensin homolog; MMP2, matrix metalloproteinase 2; Exo/Nc, negative control miRNA-loaded exosome injection; Exo/21-M, miR-21 
mimic-loaded exosome injection; Exo/21-I, miR-21 inhibitor-loaded exosome injection.
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cardiac diseases (20,37). Previously, miR-21 has been revealed 
to serve notable functions in cardiovascular disorders (28). 
Furthermore, a number of potential target genes involved in 
miR-21-mediated cardiovascular effects have also been iden-
tified (28). For instance, miR‑21 regulates the extracellular 
regulated kinase‑mitogen activated pathway kinase signaling 
pathway in cardiac fibroblasts, which impacts cardiac struc-
ture and function (20). Furthermore, miR-21 serves a critical 
function in cardiac fibroblast activation and cardiac fibrosis 
following MI via the tumor growth factor-β/Smad7 signaling 
pathway (19). In addition, modulation of the miR-21-regulated 
expression of MMP-2 via the PTEN pathway regulates 
cardiac fibrosis (18,31). Altogether, these results confirm that 
miR-21 may function as a therapeutic target for MI; thus the 
present study examined miR-21 loaded into human peripheral 
blood-derived exosomes.
Exosomes a re smal l membrane-bound vesicles 
(30-100 nm) secreted by most cell types. Exosomes serve 
a major function in cell-to-cell communication that may 
affect neighboring cells and distant parts of the body 
by transferring molecules, including proteins, mRNAs 
and miRNAs (9,38,39). The natural biocompatibility of 
Figure 5. Effects of miR‑21 mimic‑ or inhibitor‑loaded exosomes on cardiac fibrosis in mice. (A) Representative images of M‑mode echocardiography demon-
strating the LV wall motion of the infarcted hearts, and the mean data of LVEF and LVFS. *P<0.05 with comparisons shown by lines. (B) Representative 
haemotoxylin and eosin staining in the border zone of the infarcted hearts (scale bar, 50 µm; magnification, x200). Pink staining indicates cardiac myocytes; 
blue staining indicates nuclei. (C) Representative Masson's Trichrome staining of mouse heart sections 1 week after MI (scale bar, 50 µm; magnification: Top 
row, x2; bottom row, x200). Blue staining indicates scar tissue; red staining indicates viable myocardium. Bar graphs exhibit the infarct wall thickness and the 
percentage of the fibrotic area (n=4 mice in each group). (D) Collagen I and III mRNA expression levels in the infarcted hearts were measured using reverse 
transcription-quantitative polymerase chain reaction. *P<0.05 and **P<0.01 with comparisons shown by lines. miR, microRNA; MI, myocardial infarction; 
Exo/Nc, negative control miRNA-loaded exosome injection; Exo/21-M, miR-21 mimic-loaded exosome injection; Exo/21-I, miR-21 inhibitor-loaded exosome 
injection; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening.
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exosomes with mammalian cells suggests that they may 
overcome the majority of cellular barriers and drug delivery 
hurdles, including RNase susceptibility, endosomal accu-
mulation, phagocytosis, multidrug resistance, cytotoxicity 
and immunogenicity (40,41). However, exosome safety 
and quantity may constitute major issues in their applica-
tion in clinical practice (14). As human peripheral blood 
has been used extensively for transfusions and is readily 
available, exosomes isolated from human peripheral blood 
may circumvent these issues. Furthermore, considering the 
systemic administration limitations of exosomes, including 
accumulation in the liver, spleen and lungs or rapid clear-
ance by macrophages (42-44), direct injection or additional 
genetic modification of peripheral blood‑derived exosome, 
as suggested by Kim et al (45), may increase the efficacy 
of their delivery to the heart by preventing non-specific 
delivery to other organs, thus increasing their therapeutic 
efficacy in clinical settings.
In conclusion, these results suggest that human peripheral 
blood‑derived exosomes function as efficient vehicles for the 
delivery of miRNAs, which in turn may potentially be used 
for the treatment of cardiac diseases. This approach may 
be further applied to therapeutic tools for various diseases, 
including cancer, by delivering miRNAs other than miR-21 or 




The present study was supported by research grants from 
the Basic Science Research Program through the National 
Research Foundation of Korea (grant no. 2017R1A2B3003303), 
the Ministry of Education, Science and Technology (grant 
no. NRF-2017R1A2B3003303) and the Korean Healthcare 
Technology R&d project funded by the Ministry of Health 
and Welfare (grant no. HI16C0058).
Availability of data and materials
The datasets used and/or analyzed during the current study are 
available from the corresponding author on reasonable request.
Authors' contributions
JK, HyelimP and BJ conceived and designed the experiments. 
JK and HyewonP performed the experiments. JK, HK and dM 
analyzed the data. JK, NY and BJ wrote the manuscript. All 
authors read and approved the final manuscript.
Ethics approval and consent to participate
The study protocol was ethically approved by the Institutional 
Review Board of Severance Hospital and adhered to the prin-
ciples of the Declaration of Helsinki. All animal experiments 
were ethically approved by the Institutional Animal care and 
Use committee of Yonsei University college of Medicine 
(approval reference no. 2011‑0136).
Patient consent for publication
Written informed consent was obtained from the subjects for 
participation in the present study study.
Competing interests
The authors declare that they have no competing interests.
References
 1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, chaitman BR 
and White Hd: Third universal definition of myocardial infarc-
tion. J Am Coll Cardiol 60: 1581‑1598, 2012.
 2. Swynghedauw B: Molecular mechanisms of myocardial 
remodeling. Physiol Rev 79: 215‑262, 1999.
 3. Nian M, Lee P, Khaper N and Liu P: Inflammatory cytokines and 
postmyocardial infarction remodeling. circ Res 94: 1543-1553, 
2004.
 4. Sun M, dawood F, Wen WH, chen M, dixon I, Kirshenbaum LA 
and Liu PP: Excessive tumor necrosis factor activation after 
infarction contributes to susceptibility of myocardial rupture and 
left ventricular dysfunction. circulation 110: 3221-3228, 2004.
 5. Regula KM and Kirshenbaum LA: Apoptosis of ventricular 
myocytes: A means to an end. J Mol cell cardiol 38: 3-13, 2005.
 6. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L 
and Narula J: Myocardial remodeling after infarction: The role 
of myofibroblasts. Nat Rev Cardiol 7: 30‑37, 2010.
 7. Zamilpa R and Lindsey ML: Extracellular matrix turnover and 
signaling during cardiac remodeling following MI: causes and 
consequences. J Mol Cell Cardiol 48: 558‑563, 2010.
 8. Fan Z and Guan J: Antifibrotic therapies to control cardiac 
fibrosis. Biomater Res 20: 13, 2016.
 9. Urbanelli L, Magini A, Buratta S, Brozzi A, Sagini K, Polchi A, 
Tancini B and Emiliani c: Signaling pathways in exosomes 
biogenesis, secretion and fate. Genes (Basel) 4: 152-170, 2013.
10. Lin J, Li J, Huang B, Liu J, chen X, chen XM, Xu YM, Huang LF 
and Wang XZ: Exosomes: Novel biomarkers for clinical diag-
nosis. ScientificWorldJournal 2015: 657086, 2015.
11. Ha d, Yang N and Nadithe V: Exosomes as therapeutic drug 
carriers and delivery vehicles across biological membranes: 
Current perspectives and future challenges. Acta Pharm Sin B 6: 
287‑296, 2016.
12. Théry c, Zitvogel L and Amigorena S: Exosomes: composition, 
biogenesis and function. Nat Rev Immunol 2: 569‑579, 2002.
13. Batrakova EV and Kim MS: Development and regulation 
of exosome-based therapy products. Wiley Interdiscip Rev 
Nanomed Nanobiotechnol 8: 744‑757, 2016.
14. Batrakova EV and Kim MS: Using exosomes, naturally‑equipped 
nanocarriers, for drug delivery. J Control Release 219: 396‑405, 
2015.
15. Boon RA and dimmeler S: MicroRNAs in myocardial infarc-
tion. Nat Rev cardiol 12: 135-142, 2015.
16. Sun T, dong YH, du W, Shi cY, Wang K, Tariq MA, Wang JX 
and Li PF: The role of microRNAs in myocardial infarction: From 
molecular mechanism to clinical application. Int J Mol Sci 18, 
2017.
17. Wang J, Huang W, Xu R, Nie Y, cao X, Meng J, Xu X, Hu S and 
Zheng Z: MicroRNA‑24 regulates cardiac fibrosis after myocar-
dial infarction. J Cell Mol Med 16: 2150‑2160, 2012.
18. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, 
Gnyawali S, Shilo S, Nuovo GJ and Sen cK: MicroRNA 
expression in response to murine myocardial infarction: miR-21 
regulates fibroblast metalloprotease‑2 via phosphatase and tensin 
homologue. cardiovasc Res 82: 21-29, 2009.
19. Yuan J, chen H, Ge d, Xu Y, Xu H, Yang Y, Gu M, Zhou Y, 
Zhu J, Ge T, et al: Mir‑21 promotes cardiac fibrosis after myocar-
dial infarction via targeting Smad7. cell Physiol Biochem 42: 
2207-2219, 2017.
20. Thum T, Gross c, Fiedler J, Fischer T, Kissler S, Bussen M, 
Galuppo P, Just S, Rottbauer W, Frantz S, et al: MicroRNA-21 
contributes to myocardial disease by stimulating MAP kinase 
signalling in fibroblasts. Nature 456: 980‑984, 2008.
21. Livak KJ and Schmittgen TD: Analysis of relative gene expres-
sion data using real-time quantitative PcR and the 2(-delta delta 
c(T)) method. Methods 25: 402-408, 2001.
KANG et al:  HUMAN PERIPHERAL BLOOd-dERIVEd EXOSOMES FOR microRNA dELIVERY2328
22. Park H, Ku SH, Park H, Hong J, Kim d, choi BR, Pak HN, 
Lee MH, Mok H, Jeong JH, et al: RAGE siRNA-mediated gene 
silencing provides cardioprotection against ventricular arrhyth-
mias in acute ischemia and reperfusion. J control Release 217: 
315‑326, 2015.
23. Bala S, Csak T, Momen‑Heravi F, Lippai d, Kodys K, catalano d, 
Satishchandran A, Ambros V and Szabo G: Biodistribution and 
function of extracellular miRNA-155 in mice. Sci Rep 5: 10721, 
2015.
24. National Research council (US) Institute for Laboratory Animal 
Research: Guide for the care and Use of Laboratory Animals. 
National Academies Press, Washington, DC, 1996.
25. Bartel dP: MicroRNAs: Target recognition and regulatory func-
tions. Cell 136: 215‑233, 2009.
26. carthew RW and Sontheimer EJ: Origins and mechanisms of 
miRNAs and siRNAs. Cell 136: 642‑655, 2009.
27. Wang B, Hao J, Jones Sc, Yee MS, Roth Jc and dixon IM: 
Decreased Smad 7 expression contributes to cardiac fibrosis in 
the infarcted rat heart. Am J Physiol Heart circ Physiol 282: 
H1685‑H1696, 2002.
28. cheng Y and Zhang c: MicroRNA-21 in cardiovascular disease. 
J cardiovasc Transl Res 3: 251-255, 2010.
29. Oudit GY and Penninger JM: cardiac regulation by phos-
phoinositide 3‑kinases and PTEN. Cardiovasc Res 82: 250‑260, 
2009.
30. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM 
and Backx PH: The role of phosphoinositide‑3 kinase and PTEN 
in cardiovascular physiology and disease. J Mol cell cardiol 37: 
449-471, 2004.
31. Tao H, Zhang JG, Qin RH, dai c, Shi P, Yang JJ, deng ZY and 
Shi KH: LncRNA GAS5 controls cardiac fibroblast activation 
and fibrosis by targeting miR‑21 via PTEN/MMP-2 signaling 
pathway. Toxicology 386: 11‑18, 2017.
32. chi JS and Kloner RA: Stress and myocardial infarction. 
Heart 89: 475‑476, 2003.
33. Travers JG, Kamal FA, Robbins J, Yutzey KE and Blaxall Bc: 
Cardiac fibrosis: The fibroblast awakens. Circ Res 118: 1021‑1040, 
2016.
34. Gu H, Liu Z, Li Y, Xie Y, Yao J, Zhu Y, Xu J, Dai Q, Zhong c, 
Zhu H, et al: Serum-derived extracellular vesicles protect against 
acute myocardial infarction by regulating miR-21/Pdcd4 
signaling pathway. Front Physiol 9: 348, 2018.
35. Khan M, Nickoloff E, Abramova T, Johnson J, Verma SK, 
Krishnamurthy P, Mackie AR, Vaughan E, Garikipati VN, 
Benedict c, et al: Embryonic stem cell-derived exosomes promote 
endogenous repair mechanisms and enhance cardiac function 
following myocardial infarction. Circ Res 117: 52‑64, 2015.
36. catalanotto c, cogoni c and Zardo G: MicroRNA in control 
of gene expression: An overview of nuclear functions. Int J Mol 
Sci 17, 2016.
37. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, 
Zender L, Magnus J, Ridzon d, et al: A microRNA component 
of the p53 tumour suppressor network. Nature 447: 1130‑1134, 
2007.
38. Théry c: Exosomes: Secreted vesicles and intercellular commu-
nications. F1000 Biol Rep 3: 15, 2011.
39. Zhang J, Li S, Li L, Li M, Guo c, Yao J and Mi S: Exosome 
and exosomal microRNA: Trafficking, sorting, and function. 
Genomics Proteomics Bioinformatics 13: 17-24, 2015.
40. Syn NL, Wang L, chow EK, Lim cT and Goh Bc: Exosomes in 
cancer nanomedicine and immunotherapy: Prospects and chal-
lenges. Trends Biotechnol 35: 665‑676, 2017.
41. Usman WM, Pham TC, Kwok YY, Vu LT, Ma V, Peng B, chan YS, 
Wei L, chin SM, Azad A, et al: Efficient RNA drug delivery 
using red blood cell extracellular vesicles. Nat commun 9: 2359, 
2018.
42. Charoenviriyakul C, Takahashi Y, Morishita M, Matsumoto A, 
Nishikawa M and Takakura Y: Cell type‑specific and common 
characteristics of exosomes derived from mouse cell lines: Yield, 
physicochemical properties, and pharmacokinetics. Eur J Pharm 
Sci 96: 316‑322, 2017.
43. Smyth T, Kullberg M, Malik N, Smith‑Jones P, Graner MW 
and Anchordoquy TJ: Biodistribution and delivery efficiency 
of unmodified tumor‑derived exosomes. J Control Release 199: 
145-155, 2015.
44. Takahashi Y, Nishikawa M, Shinotsuka H, Matsui Y, Ohara S, 
Imai T and Takakura Y: Visualization and in vivo tracking of 
the exosomes of murine melanoma B16‑BL6 cells in mice after 
intravenous injection. J Biotechnol 165: 77‑84, 2013.
45. Kim H, Yun N, Mun d, Kang JY, Lee SH, Park H, Park H and 
Joung B: Cardiac‑specific delivery by cardiac tissue‑targeting 
peptide-expressing exosomes. Biochem Biophys Res 
commun 499: 803-808, 2018.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International (CC BY-NC-ND 4.0) License.
